Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.8%
    Check dated 2025-07-04T00:56:50.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    22 days ago
    Change Detected
    Summary
    The timeline for the modernization of the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025, with API users still able to provide input beforehand.
    Difference
    1%
    Check dated 2025-06-19T17:19:42.000Z thumbnail image
  4. Check
    36 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:19:02.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T06:05:48.000Z thumbnail image
  6. Check
    72 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T14:22:06.000Z thumbnail image
  7. Check
    86 days ago
    Change Detected
    Summary
    The webpage has undergone significant content changes, including the removal of detailed study descriptions and inclusion criteria for a clinical trial on non-small cell lung cancer, while adding a new revision number and a study identifier.
    Difference
    46%
    Check dated 2025-04-16T10:37:32.000Z thumbnail image

Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.